Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma

Epigenetics

Volumn 8, Issue 4, 2013, Pages 373-382

  Zhang, Xiaomei ^a   Yang, Yunsheng ^a   Liu, Xuefeng ^a   Herman, James G ^b   Brock, Malcolm V ^b   Licchesi, Julien D F ^b   Yue, Wen ^c   Pei, Xuetao ^c   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

DACT2; DNA methylation; Epigenetics; Hepatocellular carcinoma; Wnt signaling

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA CATENIN; BROXURIDINE; DAPPER DISHEVELLED ASSOCIATED ANTAGONIST OF BETA CATENIN HOMOLOG 2; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; AZACITIDINE; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CARRIER PROTEIN; DACT2 PROTEIN, HUMAN; DECITABINE; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETIC REPRESSION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING; WNT SIGNALING PATHWAY; AGED; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; METABOLISM; METHYLATION; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE; XENOGRAFT;

ADULT; AGED; ANIMALS; APOPTOSIS; AZACITIDINE; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIGENESIS, GENETIC; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MALE; METHYLATION; MICE, NUDE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84875835697     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.24113     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi. org/10.3322/caac.20107.
2. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 2006; 12:4515-22; PMID:16899597; http://dx.doi.org/10.1158/1078-0432.CCR-05-2858.
3. Zhang XM, Guo MZ. The value of epigenetic markers in esophageal cancer. Front Med China 2010; 4:378-84; PMID:21107750; http://dx.doi.org/10.1007/ s11684-010-0230-3.
4. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6:107-16; PMID:16491070; http://dx.doi.org/10.1038/nrc1799.
5. Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics 2010; 5:743-9; PMID:20716954; http://dx.doi.org/10.4161/ epi.5.8.13104.
6. Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med 2006; 354:2193-4; PMID:16707764; http://dx.doi.org/10.1056/ NEJMc052698.
7. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer 2007; 121:1219-26; PMID:17534889; http://dx.doi.org/10.1002/ ijc.22828.
8. Guo M, House MG, Akiyama Y, Qi Y, Capagna D, Harmon J, et al. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer 2006; 119:2078-83; PMID:16823849; http://dx.doi. org/10.1002/ijc.22092.
9. Liu W, Li X, Chu ES, Go MY, Xu L, Zhao G, et al. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology 2011; 53:843-53; PMID:21319196; http://dx.doi.org/10.1002/ hep.24124.
10. Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2011; 55:1453-61; http:// dx.doi.org/10.1002/hep.25512.
11. Wang Y, Lee CG. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics 2011; 3:235-43; PMID:22122284; http://dx.doi.org/10.2217/epi.11.5.
12. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, et al. DACT3 is an epigenetic regulator of Wnt/ beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008; 13:529-41; PMID:18538736; http://dx.doi. org/10.1016/j.ccr.2008.04.019.
13. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8:387-98; PMID:18432252; http://dx.doi. org/10.1038/nrc2389.
14. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/betacatenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 2008; 48:780-91; PMID:18313787; http://dx.doi.org/10.1016/j.jhep.2007.12.020.
15. Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008; 99:143-50; PMID:18577996; http://dx.doi.org/10.1038/ sj.bjc.6604422.
16. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11:1901-15; PMID:16368566; http://dx.doi. org/10.2741/1933.
17. Cheyette BN, Waxman JS, Miller JR, Takemaru K, Sheldahl LC, Khlebtsova N, et al. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. Dev Cell 2002; 2:449-61; PMID:11970895; http:// dx.doi.org/10.1016/S1534-5807(02)00140-5.
18. Katoh M, Katoh M. Identification and characterization of human DAPPER1 and DAPPER2 genes in silico. Int J Oncol 2003; 22:907-13; PMID:12632086.
19. Fisher DA, Kivimäe S, Hoshino J, Suriben R, Martin PM, Baxter N, et al. Three Dact gene family members are expressed during embryonic development and in the adult brains of mice. Dev Dyn 2006; 235:2620-30; PMID:16881060; http://dx.doi.org/10.1002/ dvdy.20917.
20. Yau TO, Chan CY, Chan KL, Lee MF, Wong CM, Fan ST, et al. HDPR1, a novel inhibitor of the WNT/ beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylationmediated gene silencing. Oncogene 2005; 24:1607-14; PMID:15580286; http://dx.doi.org/10.1038/ sj.onc.1208340.
21. Xun WW, Brennan P, Tjonneland A, Vogel U, Overvad K, Kaaks R, et al. Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC). Mutagenesis 2011; 26:657-66; PMID:21750227; http://dx.doi.org/10.1093/mutage/ger030.
22. Li BC, Chan WY, Li CY, Chow C, Ng EK, Chung SC. Allelic loss of chromosome 6q in gastric carcinoma. Diagn Mol Pathol 2003; 12:193-200; PMID:14639105; http://dx.doi.org/10.1097/00019606-200312000-00003.
23. Carvalho B, van der Veen A, Gärtner F, Carneiro F, Seruca R, Buys CH, et al. Allelic gains and losses in distinct regions of chromosome 6 in gastric carcinoma. Cancer Genet Cytogenet 2001; 131:54-9; PMID:11734319; http://dx.doi.org/10.1016/S0165-4608(01)00514-3.
24. Qu XY, Hauptschein RS, Rzhetsky A, Scotto L, Chien MC, Ye X, et al. Analysis of a 69-kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. DNA Seq 1998; 9:189-204; PMID:10520750.
25. Rodriguez C, Causse A, Ursule E, Theillet C. At least five regions of imbalance on 6q in breast tumors, combining losses and gains. Genes Chromosomes Cancer 2000; 27:76-84; PMID:10564589; h t t p: / / d x. d o i. o r g / 1 0. 1 0 0 2 / (S I C I) 1 0 9 8-2264(200001)27:1<76::AID-GCC10>3.0. CO;2-E.
26. Minaguchi T, Matsushima M, Saito S, Kanamori Y, Shirahama S, Okamoto S, et al. Complete DNA sequence and characterization of a 330-kb VNTRrich region on chromosome 6q27 that is commonly deleted in ovarian cancer. DNA Res 1999; 6:131-6; PMID:10382971; http://dx.doi.org/10.1093/ dnares/6.2.131.
27. Liu Y, Emilion G, Mungall AJ, Dunham I, Beck S, Le Meuth-Metzinger VG, et al. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene 2002; 21:387-99; PMID:11821951; http://dx.doi. org/10.1038/sj.onc.1205067.
28. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, et al. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 2003; 12:1251-60; PMID:14636582; http://dx.doi.org/10.1016/ S1097-2765(03)00427-1.
29. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5:997-1014; PMID:17139285; http://dx.doi.org/10.1038/ nrd2154.
30. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, et al. Downregulation of Dkk3 activates betacatenin/ TCF-4 signaling in lung cancer. Carcinogenesis 2008; 29:84-92; PMID:18048388; http://dx.doi. org/10.1093/carcin/bgm267.
31. Gao X, Wen J, Zhang L, Li X, Ning Y, Meng A, et al. Dapper1 is a nucleocytoplasmic shuttling protein that negatively modulates Wnt signaling in the nucleus. J Biol Chem 2008; 283:35679-88; PMID:18936100; http://dx.doi.org/10.1074/jbc.M804088200.
32. Waxman JS, Hocking AM, Stoick CL, Moon RT. Zebrafish Dapper1 and Dapper2 play distinct roles in Wnt-mediated developmental processes. Development 2004; 131:5909-21; PMID:15539487; http://dx.doi. org/10.1242/dev.01520.
33. Gillhouse M, Wagner Nyholm M, Hikasa H, Sokol SY, Grinblat Y. Two Frodo/Dapper homologs are expressed in the developing brain and mesoderm of zebrafish. Dev Dyn 2004; 230:403-9; PMID:15188426; http:// dx.doi.org/10.1002/dvdy.20060.
34. Waxman JS. Regulation of the early expression patterns of the zebrafish Dishevelled-interacting proteins Dapper1 and Dapper2. Dev Dyn 2005; 233:194-200; PMID:15765513; http://dx.doi.org/10.1002/ dvdy.20301.
35. Teran E, Branscomb AD, Seeling JM. Dpr Acts as a molecular switch, inhibiting Wnt signaling when unphosphorylated, but promoting Wnt signaling when phosphorylated by casein kinase Idelta/epsilon. PLoS One 2009; 4:e5522; PMID:19440376; http://dx.doi. org/10.1371/journal.pone.0005522.
36. Kivimäe S, Yang XY, Cheyette BN. All Dact (Dapper/ Frodo) scaffold proteins dimerize and exhibit conserved interactions with Vangl, Dvl, and serine/threonine kinases. BMC Biochem 2011; 12:33; PMID:21718540; http://dx.doi.org/10.1186/1471-2091-12-33.
37. Su Y, Zhang L, Gao X, Meng F, Wen J, Zhou H, et al. The evolutionally conserved activity of Dapper2 in antagonizing TGF-beta signaling. FASEB J 2007; 21:682-90; PMID:17197390; http://dx.doi. org/10.1096/fj.06-6246com.
38. Zhang L, Zhou H, Su Y, Sun Z, Zhang H, Zhang L, et al. Zebrafish Dpr2 inhibits mesoderm induction by promoting degradation of nodal receptors. Science 2004; 306:114-7; PMID:15459392; http://dx.doi. org/10.1126/science.1100569.
39. Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M. Epigenetic Regulation of DACT2, A Key Component of the Wnt Signaling Pathway in Human Lung Cancer. [Epub ahead of print]. J Pathol 2012; PMID:22806826; http://dx.doi.org/10.1002/ path.4073.
40. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93:9821-6; PMID:8790415; http:// dx.doi.org/10.1073/pnas.93.18.9821.
41. Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008; 68:2764-72; PMID:18413743; http://dx.doi.org/10.1158/0008-5472.CAN-07-6349.
42. Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009; 27:3908-15; PMID:19620495; http://dx.doi.org/10.1200/JCO.2008.18.1925.
43. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16:3797-804; PMID:9233789; http://dx.doi.org/10.1093/ emboj/16.13.3797.